Skip to Content
  • 3.1
    Impact Factor
  • 5.9
    CiteScore
  • 14 days
    Submission to First Decision
  • 4 days
    Acceptance to Publication

Genes

Genes is a peer-reviewed, open access journal of genetics and genomics published monthly online by MDPI. The Epigenetics Society (ES) and the Spanish Society for Nitrogen Fixation (SEFIN) are affiliated with Genes, and their members receive discounts on the article processing charges.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (15,403)

  • Article
  • Open Access

Background: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy in which pathogenesis and clinical outcomes are closely associated with genetic factors. The interferon regulatory factor (IRF) gene family plays an important role in immune regulation and tumorigenesis; however, the implications of IRF single-nucleotide polymorphisms (SNPs) in DLBCL remain unclear. Methods: We conducted genotyping analysis of 15 SNPs in the IRF genes using the MassARRAY system in 133 DLBCL patients. The associations of these SNPs with clinical characteristics, treatment response, and survival outcomes were evaluated using Pearson’s chi-square test or Fisher’s exact test, and univariate binary logistic regression. The impact of SNPs on survival outcomes was evaluated with Kaplan–Meier survival curves and log-rank tests. Results: The IRF9 rs4981494 variant was associated with a lower likelihood of no bulky disease and the non-Germinal Center B-cell (non-GCB) subtype in patients with DLBCL. Similarly, IRF4 rs7768807 was associated with a lower likelihood of extranodal involvement at two or more sites. Furthermore, IRF4 rs2316515 was associated with poorer treatment response and shorter progression-free survival (PFS), with the association with PFS remaining significant after multivariable adjustment. Conclusions: Our findings suggest that IRF SNPs may serve as potential biomarkers for treatment response and prognostic stratification in patients with DLBCL, although further validation is warranted.

Genes

21 November 2026

Biological Functions of the Interferon Regulatory Factor (IRF) Family and Their Roles in Hematological Malignancies. ↑/↓indicate increased or decreased expression or activity of IRF family members, respectively.
  • Article
  • Open Access

Background/Objectives: Acetylalkannin has reported activity in liver cancer cells, but its candidate protein targets in hepatocellular carcinoma (HCC) remain incompletely characterized. We sought to identify interactions for experimental testing. Methods: We combined compound–target prediction, network analysis, molecular docking, molecular dynamics (MD), and molecular mechanics/Poisson–Boltzmann surface area (MM-PBSA) estimates. We used The Cancer Genome Atlas liver hepatocellular carcinoma (TCGA-LIHC) cohort to examine candidate-gene expression and clinical associations. Results: Network analysis reduced 181 shared targets to 22 consensus targets and a 17-gene panel. The final network defined 52 compound–target pairs for docking. Six ranked complexes were selected for follow-up, and five completed 100 ns simulations. Candidate membership depended on network settings, and only two complexes ranked in the top six under both scoring schemes. Acetylalkannin had the lowest two mean ligand deviations in the EGFR and MTOR simulations. The interaction entropy correction varied with the frames sampled. Among 371 primary tumors and 50 adjacent samples, EGFR expression was lower in tumors, and the MTOR difference was not significant. In 341 patients, after adjustment for age and pathological stage and correction for multiple testing, EGFR, MTOR, and HSP90AA1 expression was not significantly associated with overall survival. PI3K–Akt signaling was positively enriched in the group with higher combined EGFR and MTOR expression. Conclusions: EGFR and MTOR warrant structural and functional follow-up, with HSP90AA1 as a comparator. The MTOR model covers the FRB domain. Direct binding, pathway regulation, and effects on HCC cells require experimental testing.

Genes

21 November 2026

Study workflow. Compound and target prioritization, molecular simulations, and TCGA-LIHC associations were integrated to generate a hypothesis for experimental testing. HCC, hepatocellular carcinoma; PPI, protein–protein interaction; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MD, molecular dynamics; TCGA, The Cancer Genome Atlas. The mountain thumbnail is a schematic enrichment icon, not an additional analysis. * denotes q < 0.05, ** denotes q < 0.01, *** denotes q < 0.001, and ns denotes q ≥ 0.05.
  • Article
  • Open Access

Background: Hepatocellular carcinoma (HCC) is an aggressive malignancy with a poor prognosis, and the post-transcriptional programs that sustain its malignant phenotype remain incompletely defined. In the competing endogenous RNA (ceRNA) model, transcripts that share microRNA response elements can influence each other’s stability, yet in vivo tissue-level evidence for the Orc1/miR-124-3p/Smyd3 axis in HCC is still lacking. The present work characterized this axis in an experimental HCC model and, in parallel, examined the expression of its downstream effector SMYD3 and its relationship with patient survival in human HCC. Methods: An H22 subcutaneous xenograft model was established in Kunming mice, and normal liver tissue from phosphate-buffered saline-injected animals served as the control. Orc1, Smyd3 and miR-124-3p were quantified by RT-qPCR, and Smyd3 protein was examined by immunofluorescence. Experimentally validated miR-124-3p–target pairs for mouse and human were retrieved from miRNet 2.0, DIANA-TarBase and miRTarBase. SMYD3 mRNA and protein expression in human HCC were assessed in the Human Protein Atlas (HPA), the prognostic value of SMYD3 was evaluated in the TCGA-LIHC cohort, and SMYD3-interacting proteins and enriched Gene Ontology (GO) terms were analyzed with STRING. Results: Database curation confirmed experimentally validated targeting of Orc1 and Smyd3 by mmu-miR-124-3p and of ORC1 and SMYD3 by hsa-miR-124-3p. In mouse HCC tissue, Orc1 (p = 0.0002) and Smyd3 (p < 0.0001) mRNA were significantly increased and miR-124-3p was significantly decreased (p < 0.0001) relative to normal liver, and Smyd3 immunofluorescence was predominantly nuclear and appeared stronger in tumor tissue. In human HCC, both SMYD3 mRNA and protein were upregulated, and higher SMYD3 expression was independently associated with shorter overall survival (HR = 1.385, 95% CI 1.144–1.678, p = 0.001). SMYD3 partners were enriched in chromatin remodeling and DNA replication-related processes. Conclusions: Considered together with previously published in vitro targeting data, these results indicate that the Orc1/miR-124-3p/Smyd3 axis shows ceRNA-consistent expression changes in mouse HCC tissue, and that its downstream effector SMYD3 is upregulated in human HCC and associated with survival. The evidence is correlative; direct binding and causal regulation of this axis remain to be demonstrated in cell-based perturbation experiments.

Genes

21 November 2026

Experimentally validated miRNA–target network of SMYD3 and ORC1 retrieved from miRNet 2.0. (A) Human network; (B) mouse network. miRNAs are shown as green nodes and target transcripts as colored circles; hsa-miR-124-3p (A) and mmu-miR-124-3p (B) are the shared nodes connected to both SMYD3/ORC1 and Smyd3/Orc1. All edges represent experimentally validated interactions archived in public databases and therefore reproduce previously published evidence rather than novel findings of this study.
  • Review
  • Open Access

When the technologies enabling cytogenetics/karyotyping and molecular genetics/sequencing were initially developed, they examined DNA variation differences at the opposite ends of the length spectrum. Karyotyping could detect only enormous changes at the chromosome level and sequencing could only distinguish changes involving single to tens of nucleotides. In the decades since their original introduction, they have both expanded the size ranges of detectable variants, converging toward each other and closing the gap on previously dark regions of the genome. In addition, novel technologies have emerged over that time frame that provide new methods for examining DNA variation and these have further closed the gap between cytogenetics and molecular genetics. The sheer number of genome analysis technologies makes it impractical to use all methods against all samples. Thus, having an understanding of when each technology is most appropriate and how the various options might complement each other is important. Furthermore, each technology will continue to evolve so knowing the future possibilities is also important. One such emerging new technology is electronic genome mapping. Because this technology has only recently been commercialized, information on how it works, what value it can bring, and how it fits in the current ecosystem of genomic methods is not widely available. This review presents a broad overview of how the technology works and how it fits with extant methods.

Genes

21 November 2026

Discovery and Product Timeline. Key scientific discoveries relating to genomics are shown to the left of the timeline. Key commercial developments that followed these discoveries are shown to the right with the company name, product and functionality shown. (NGS: Next generation sequencing).

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Genes - ISSN 2073-4425